4518 results about "RNA" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

Provided herein are methods of identifying abundance and location of an RNA in a biological sample using an adaptor sequence and a primer. Also disclosed herein are kits. compositions, and systems that are used to perform the methods.

Provided herein are methods, kits, and compositions for determining the spatial location of non-coding RNA, such as siRNA and / or miRNA in a biological sample.

Provided herein are methods and compositions disclosing an approach that combines single nuclear RNA-seq (snRNA-seq) with spatial transcriptomics. The methods include processing and analyzing multiple analytes in a biological sample, and utilizes multiple substrates, one having a spatial array having a plurality of capture probes, each having a capture domain and a spatial barcode. The methods can be used to detect location of both nucleic acid and protein analytes. The methods also include isolating cells and / or nuclei from a sample and determining analyte expression in the isolated cells and / or nuclei.

Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3′ end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3′ of the positional domain.

Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3′ end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3′ of the positional domain.

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1

Aspects of the disclosure relate to methods of reducing expression or activity of DMPK (e.g., reducing the level of a mutant or wild-type DMPK RNA, or the activity of a DMPK gene product) and / or methods of treating myotonic dystrophy (e.g., DM1) in a subject. In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising an oligonucleotide (e.g., a DMPK—targeting oligonucleotide) covalently linked to an antibody (e.g., anti-TfR1 antibody).

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention discloses a multi-omics pathological analysis system and method for colorectal cancer liver metastasis risk prediction, and relates to the technical field of biomedicine and cancer diagnosis, the system comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; according to the method, multiple omics data including the single cell data set, the space transcriptome data, the batch RNA-seq data, the clinical data and the full slice image WSIs are integrated, comprehensive and accurate prediction of the colorectal cancer liver metastasis risk is achieved, cross-dimensional data fusion and analysis improve the prediction accuracy and reliability, and the risk of the colorectal cancer liver metastasis is reduced. The invention also provides a powerful tool for deeply exploring the molecular mechanism of tumorigenesis, development and metastasis, and particularly in a cell analysis module, cell subtypes and molecular characteristics closely related to liver metastasis can be disclosed by identifying and analyzing malignant cell subgroups LMTMCs triggering liver metastasis, so that the liver metastasis can be discovered. And a scientific basis is provided for formulating a personalized treatment scheme.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to dsRNA for preventing and treating crop anthracnose and application of the dsRNA. The dsRNA is targeted inositol phosphatidylceramide (IPC) synthetase coding gene dsRNA, and is obtained by transcription of a part of sequence (SEQ ID No.1) of an inositol phosphatidylceramide (IPC) synthetase coding gene CaAUR1, the gene segment is a segment of a target gene for preventing and treating crop anthracnose, and the dsRNA obtained by transcription can obviously reduce pathogenicity of mango anthracnose bacteria, and has the effects of keeping mango fresh, preventing and treating anthracnose. And the compound can be used for preventing and treating the crop anthracnose or preparing products for preventing and treating the crop anthracnose.

The invention provides a modified TnpB-omega RNA gene editing system and application of the modified TnpB-omega RNA gene editing system. In particular, the present invention provides a modified TnpB related [omega] RNA skeleton. The modified omega RNA skeleton provided by the invention has at least three stem-loop structure fragments, and has a shorter length and a compact structure than a natural omega RNA skeleton, so that the modified omega RNA skeleton and TnpB can be jointly carried in a single AAV vector, the administration efficiency is improved, and high-efficiency gene editing is realized.

The invention discloses an intestinal cancer metastasis prediction method and device based on spatial omics, a medium and equipment, and the method comprises the steps: collecting original multi-omics data, and carrying out modal alignment and quality control processing to obtain pre-processed multi-omics data comprising second spatial transcriptome data, second single-cell RNA sequencing data and second pathological image data; performing cross-modal semantic embedding on the second spatial transcriptome data based on the second single-cell RNA sequencing data to generate a spatial enhanced expression profile; performing multi-scale graph construction on the second spatial transcriptome data and the second pathological image data, and extracting spatial heterogeneity features; inputting the spatial enhancement expression spectrum and the spatial heterogeneity features into a pre-trained metastasis risk prediction model, and outputting a liver metastasis probability spatial heat map and a key driving feature list; and finally generating a clinical prediction report containing high-risk area positioning. According to the method, through dynamic optimization of spatial resolution and multi-scale feature collaborative modeling, the sensitivity of early transfer detection is remarkably improved.

The invention relates to the technical field of medical image analysis, and discloses an HER2 positive breast cancer auxiliary prediction method based on multi-modal data fusion. According to the method, preoperative MRI, clinical pathology data and RNA-seq data meeting quality control standards are obtained through dynamic case screening, traditional image features, multi-scale Hessian matrix blood vessel-structure features and topological persistent coherent curvature features are extracted through multi-plane segmentation, and key features are obtained through three-level screening. A multi-factor logistic model fusing radiomics, clinical features and immune scoring is further constructed, a pCR probability value and a feature contribution heat map are output, and MRI data quality control, real-time analysis and interactive report generation are achieved through a matched computer system. The method breaks through the limitation of single modal analysis, dynamically associates the image features with the molecular mechanism, and provides interpretable decision support for precision medical treatment.

The invention discloses a rice nitrogen response regulation and control network analysis and breeding target identification system and method based on multi-omics data. According to the system, organic combination of regulation and control network construction based on single or multiple varieties of materials, key transcription factor recognition and accurate positioning of regulation and control areas where transcription factors play roles is achieved through an expression-chromatin accessibility correlation research method, and cis-trans effect distinguishing of the regulation and control areas is achieved through a deep learning model. The method comprises the following steps: carrying out nitrogen starvation pretreatment on rice, then carrying out nitrogen resupply, collecting a root sample, and carrying out ATAC-seq and RNA-seq sequencing; an eCAAS method is adopted to construct a regulation and control network, and key transcription factors are identified and accurately positioned; the chromatin accessibility difference of different varieties is predicted through a deep learning model, the cis-action effect and the trans-action effect are distinguished, an upstream transcription factor target is provided for genes dominated by the trans-effect, and haplotype and editable regulatory region targets available for direct breeding are provided for genes dominated by the cis-effect.

The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.

The invention relates to the technical field of virus whole genome sequencing, and discloses a method for virus whole genome sequencing, which comprises the following steps: S1, extracting a sample genome, operating according to a specification of a commodity kit, extracting RNA (Ribonucleic Acid) of the sample genome, and performing library construction after reverse transcription and targeted amplification. According to the method for sequencing the whole genome of the virus, the whole genome sequence of the virus can be obtained through the sequencing method, and compared with the current detection which only stays at negative and positive detection, the whole genome sequence can be obtained on the basis through the method for sequencing, epidemiological traceability is carried out, and meanwhile the sequencing cost can be effectively reduced.

A three-dimensional scaffold for use in engineered tissue includes a repeated 3D geometry; and at least one of a hydrogel, a biocompatible polymer, and a bioprintable polymer. The repeated 3D geometry may include an open geometry including a plurality of interconnected nodes configured to be seeded with living cells. The scaffold may be formed via bioprinting. The three-dimensional scaffold may also be used for (1) 3D tissue modelling (for liver, kidney, gut, pancreas, heart, lung, spleen, etc.), (2) disease modeling of different tumor types such as breast, colorectal, lung, liver, brain, ovarian and others, (3) drug testing / therapeutic screening of small molecule drugs, peptides, proteins, antibodies, ADCs, gene therapies, RNA-based therapeutics, cell therapies, and tissue therapies, and (4) therapeutic / drug delivery (i.e., via delivery device that can be used to control drug release based on different patterns).

The invention discloses a long-chain non-coding RNA molecular marker related to bovine semen quality and application of the long-chain non-coding RNA molecular marker, long-chain non-coding RNA comprises an LNC68393 promoter sequence and an LNC68393 gene sequence, a molecular marker SNP1 is located on the promoter sequence, and a molecular marker SNP2-5 is located on the gene sequence. Different polymorphisms of the molecular marker are significantly related to the bull semen quality, and the molecular marker can be applied to detection of the bull semen quality, further early evaluation of the bull reproductive performance, cultivation of excellent bulls, shortening of the breeding time, improvement of the efficiency and reduction of the cost, and has important application value in improvement of the reproductive performance of the whole bull herd.

An RNA inhibitor for inhibiting gene expression of a complement system, or a pharmaceutically acceptable salt thereof. The structure of the RNA inhibitor further contains vector structures 5'MVIP and 3'MVIP. The provided RNA inhibitor interferes with the translation template function of the mRNA of the complement system, and continuously and efficiently inhibits the gene expression of the complement system, so that CFB, C5 and C3 protein levels of the complement system in blood are continuously reduced. The RNA inhibitor can be used for treating and / or preventing diseases associated with an increased level of the complement system.

A nucleic acid molecule comprising: i) a first nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a nucleotide sequence comprising a cardiovascular disease associated gene to be silenced and wherein said cardiovascular gene is proprotein convertase subtilisin kexin 9 (PCSK9) there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand; and ii) a second nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a different cardiovascular disease associated gene to be silenced wherein said cardiovascular gene is lipoprotein (a) (Lp(a)) and wherein there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand wherein the single stranded deoxyribonucleic acid (DNA) molecule is substantially complementary to the single stranded deoxyribonucleic acid (DNA) molecule set forth in i) above and anneals by complementary base pairing to form a double stranded DNA linker that links the first and second double stranded inhibitory ribonucleic acid (RNA) molecules.

The purpose of the present invention is to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem / progenitor cell or a mesenchymal stem cell, and a method for delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule wherein the lipid nanoparticle comprises an ionizable lipid and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

Provided herein are technologies for framing and evaluating biological sequence-based analysis tasks in a unified, natural-language-based, text in and text out format. Among other things, methods and systems of the present disclosure provide machine-learning technologies for combining biological sequence data, representing, for example, DNA, RNA, and protein sequences, with natural language, conversational style prompts that set out particular analysis tasks to be performed on the biological sequence data. This approach, for example, allows complex analysis tasks, including, but not limited to, identification of various sequence modifications, genes, and regulatory elements in DNA sequences, and quantification of properties such as degradation propensity of RNA and protein stability, to be input to a machine learning model in a uniform text-based format and for output to be generated in a same, unified, text-based format.

Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.

The present invention relates to the field of tissue-derived cell identification, in particular to a method for identifying tissue-derived cells in the body fluid based on single-cell sequencing technology. In the present invention, on the basis of high-throughput single-cell RNA sequencing data of cell samples obtained from body fluids, by means of reference component analysis (RCA), expression of known tissue-related marker genes, and a tissue-derived cell prediction model constructed based on logistic regression, the specific identification of tissue-derived cells in body fluids is achieved.

The present invention discloses an interfering RNA for inhibiting PCSK9 gene and use thereof. The interfering RNA comprises a nucleotide sequence set forth in any one or two or more of SEQ ID NOs: 1-40, 73-96. The interfering RNA of the present invention can better target and silence hepatic PCSK9 mRNA, reduce the protein level of PCSK9, enhance LDL-C metabolism, and reduce serum cholesterol, providing a solid technical foundation for the development of siRNA medicaments for the prevention, treatment, and symptom alleviation of PCSK9 gene-mediated diseases.

The invention discloses an lncRNA-miRNA association prediction system and method fused with a hypergraph perspective, and belongs to the technical field of biological information. The LncRNA-miRNA association prediction method aims at solving the problem that in an existing LncRNA-miRNA association prediction method, the node representation capacity is insufficient, interaction relation modeling is not comprehensive, and consequently prediction performance is poor. According to the method, lncRNA and miRNA sequence data are obtained and subjected to data preprocessing, then K-mer frequency features, Doc2Vec semantic features, CTD structural features and Role2Vec topological features of each RNA are obtained, multi-level feature fusion is carried out to obtain unified fusion features of each RNA, then the unified fusion features are sent into GCN and HGCN networks to obtain respective corresponding features, optimization is carried out on the basis of comparative learning optimization, and the fusion features of each RNA are obtained. And then dynamic fusion is carried out, final fusion feature representation is obtained based on the gating factor, and lncRNA-miRNA association prediction is realized based on the final fusion feature representation.

This invention relates to recombinant nucleic constructs comprising a DNA binding domain, an endonuclease and a reverse transcriptase and methods of use thereof for modifying nucleic acids in plants.